Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2020-12-01
2023-07-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
NCT04613271
Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
NCT04542694
Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal
NCT04694612
An Adaptive Clinical Trial of Antivirals for COVID-19 Infection
NCT04445467
Favipiravir in High-risk COVID-19 Patients
NCT04818320
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Complications
Evaluathion
Favipiravir
Antiviral drugs
Remdesivir
Antiviral drugs
Oxygen status
Evaluathion
Favipiravir
Antiviral drugs
Remdesivir
Antiviral drugs
Oxugen support
Evaluathion
Favipiravir
Antiviral drugs
Remdesivir
Antiviral drugs
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Favipiravir
Antiviral drugs
Remdesivir
Antiviral drugs
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with COVID19 with medium and easy condition disease
* take favipiravir/remdisivir control group
* Patients with COVID19 with medium and easy condition disease
* not take favipiravir/remdisivir
Exclusion Criteria
* severe conditionis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astana Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aidos Konkayev
doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aidos Konkaev
Astana, , Kazakhstan
Semey Medical University
Semey, , Kazakhstan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.